Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Alphs

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Schizophrenia Research|March 5, 2022
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorderLarry Alphs, Brianne Brown, Ibrahim Turkoz, et al.
Clinical Schizophrenia & Related Psychoses|March 1, 2013
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensDong-Jing Fu, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
BMC Psychiatry|November 1, 2011
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptomsWayne Macfadden, Caleb M Adler, Ibrahim Turkoz, et al.
Clinical Drug Investigation|June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup AnalysisMaju Mathews, Huiling Pei, Adam Savitz, et al.
Bipolar Disorders|October 21, 2009
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Bipolar Disorders|October 17, 2009
Asenapine versus olanzapine in acute mania: a double-blind extension studyRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Schizophrenia Bulletin|January 29, 2011
Methodological issues in negative symptom trialsStephen R Marder, David G Daniel, Larry Alphs, et al.
Schizophrenia Research|April 30, 2017
Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, David Walling, et al.
The Journal of Clinical Psychiatry|May 5, 2015
The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophreniaPeter J Weiden, Rebecca S Roma, Dawn I Velligan, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Schizophrenia Research|March 5, 2022
The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorderLarry Alphs, Brianne Brown, Ibrahim Turkoz, et al.
Clinical Schizophrenia & Related Psychoses|March 1, 2013
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimensDong-Jing Fu, Cynthia A Bossie, Jennifer Kern Sliwa, et al.
BMC Psychiatry|November 1, 2011
Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptomsWayne Macfadden, Caleb M Adler, Ibrahim Turkoz, et al.
Clinical Drug Investigation|June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup AnalysisMaju Mathews, Huiling Pei, Adam Savitz, et al.
Bipolar Disorders|October 21, 2009
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Bipolar Disorders|October 17, 2009
Asenapine versus olanzapine in acute mania: a double-blind extension studyRoger S McIntyre, Miriam Cohen, Jun Zhao, et al.
Therapeutic Advances in Psychopharmacology|August 29, 2013
Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialCynthia A Bossie, Dong-Jing Fu, Jennifer Kern Sliwa, et al.
Schizophrenia Bulletin|January 29, 2011
Methodological issues in negative symptom trialsStephen R Marder, David G Daniel, Larry Alphs, et al.
Schizophrenia Research|April 30, 2017
Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorderDong-Jing Fu, Ibrahim Turkoz, David Walling, et al.
The Journal of Clinical Psychiatry|May 5, 2015
The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophreniaPeter J Weiden, Rebecca S Roma, Dawn I Velligan, et al.
Pageof 12